Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

EHA 2016

9 - 12 Jun 2016
The Bella Center, Copenhagen, Denmark
Cured AML patients generate anti-tumour antibodies that kill AML blasts
Dr Mette Hazenberg - Academic Medical Center, Amsterdam, The Netherlands
Cured AML patients generate anti-tumour antibodies that kill AML blasts ( Dr Mette Hazenberg - Academic Medical Center, Amsterdam, The Netherlands )
6 Jul 2016
Very late relapse in Hodgkins lymphoma
Dr Paul Bröckelmann - University Hospital of Cologne, Cologne, Germany
Very late relapse in Hodgkins lymphoma ( Dr Paul Bröckelmann - University Hospital of Cologne, Cologne, Germany )
6 Jul 2016
Modelling ponatinib resistance in BCR-ABL1 cell lines
Dr Liu Lu - South Australian Health and Medical Research Institute, Adelaide, Au...
Modelling ponatinib resistance in BCR-ABL1  cell lines ( Dr Liu Lu - South Australian Health and Medical Research Institute, Adelaide, Australia )
1 Jul 2016
Results from the EURO-SKI cessation trial of TKIs in CML
Dr Johan Richter - Lund University, Lund, Sweden
Results from the EURO-SKI cessation trial of TKIs in CML ( Dr Johan Richter - Lund University, Lund, Sweden )
23 Jun 2016
Mutations associated with imatinib response in CML
Katerina Machova Polakova - Institute of Hematology and Blood Transfusion, Pragu...
Mutations associated with imatinib response in CML ( Katerina Machova Polakova - Institute of Hematology and Blood Transfusion, Prague, Czech Republic )
20 Jun 2016
CD19 CAR T-cells effective with with low dose chemotherapy.
Dr Stephanie Goff - National Cancer Institute, Bethesda, USA
CD19  CAR T-cells effective with with low dose chemotherapy. ( Dr Stephanie Goff - National Cancer Institute, Bethesda, USA )
12 Jun 2016
Specific mutations in leukaemia patients' blood predicts survival
Dr Klaus Metzeler - University of Munich, Munich, Germany
Specific mutations in leukaemia patients' blood predicts survival ( Dr Klaus Metzeler - University of Munich, Munich, Germany )
12 Jun 2016
Causes and consequences of microRNA dysregulation in cancer
Prof Carlo Croce - Ohio State University, Columbus, USA
Causes and consequences of microRNA dysregulation in cancer ( Prof Carlo Croce - Ohio State University, Columbus, USA )
12 Jun 2016
Sequencing multiple myeloma reveals a complex landscape of genetic lesions
Dr Niccolo Bolli - University of Milan, Milan, Italy
Sequencing multiple myeloma reveals a complex landscape of genetic lesions ( Dr Niccolo Bolli - University of Milan, Milan, Italy )
12 Jun 2016
Results from SCHOLAR-1 trial for DLBCL patients
Prof Christian Gisselbrecht - LYSARC, Pierre-Bénite, France
Results from SCHOLAR-1 trial for DLBCL patients ( Prof Christian Gisselbrecht - LYSARC, Pierre-Bénite, France )
12 Jun 2016
Super-enhancer analysis reveals subtypes in AML and MDS
Dr Michael McKeown - Syros Pharmaceuticals, Cambridge, USA
Super-enhancer analysis reveals subtypes  in AML and MDS ( Dr Michael McKeown - Syros Pharmaceuticals, Cambridge, USA )
12 Jun 2016
PD-1 enhances elotuzumab efficacy
Dr Natalie Bezman - Bristol-Meyers Squibb, Princeton, USA
PD-1 enhances elotuzumab efficacy ( Dr Natalie Bezman - Bristol-Meyers Squibb, Princeton, USA )
12 Jun 2016
Better screening programmes needed for haematological malignancies such as leuka...
Dr Brigitte Schlegerberger - Hannover Medical School, Hannover, Germany
Better screening programmes needed for haematological malignancies such as leukaemia ( Dr Brigitte Schlegerberger - Hannover Medical School, Hannover, Germany )
12 Jun 2016
Novel therapies for older patients with AML and MDS
Prof Naval Daver - MD Anderson Cancer Center, Houston, United States
Novel therapies for older patients with AML and MDS ( Prof Naval Daver - MD Anderson Cancer Center, Houston, United States )
12 Jun 2016
Karyotyping a CLL subset with ibrutinib susceptibility
Dr Jeffrey Jones - Ohio State University, Columbus, USA
Karyotyping a CLL subset with ibrutinib susceptibility ( Dr Jeffrey Jones - Ohio State University, Columbus, USA )
12 Jun 2016
Chemo-genomic interrogation reveals JAK sensitive subgroup in AML
Dr Vincent-Philippe Lavallée - Université de Montréal, Montréal, Canada
Chemo-genomic interrogation reveals JAK sensitive subgroup in AML ( Dr Vincent-Philippe Lavallée - Université de Montréal, Montréal, Canada )
12 Jun 2016
The role of AKT in chronic lymphocytic leukaemia transformation to Richter's syn...
Dr Christian Pallasch, University Hospital of Cologne, Cologne, Germany
The role of AKT in chronic lymphocytic leukaemia transformation to Richter's syndrome ( Dr Christian Pallasch, University Hospital of Cologne, Cologne, Germany )
12 Jun 2016
Advances in first line treatment options for MCL patients
Professor Steven Le Gouill and Professor Simon Rule
Advances in first line treatment options for MCL patients ( Professor Steven Le Gouill and Professor Simon Rule )
11 Jun 2016
Targeted genome editing in haematopoeitic stem cells
Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy
Targeted genome editing in haematopoeitic stem cells ( Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy )
11 Jun 2016
A microRNA driver of B-cell leukaemia
Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy
A microRNA driver of B-cell leukaemia ( Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy )
11 Jun 2016
The latest in CLL from EHA 2016
Prof Peter Hillmen, Prof Paolo Ghia, Dr Chris Fox and Dr Constantine Tam
The latest in CLL from EHA 2016 ( Prof Peter Hillmen, Prof Paolo Ghia, Dr Chris Fox and Dr Constantine Tam )
11 Jun 2016
Safety and efficacy of imatinib generics
Prof Tomasz Sacha - Jagiellonian University, Krakow, Poland
Safety and efficacy of imatinib generics ( Prof Tomasz Sacha - Jagiellonian University, Krakow, Poland )
11 Jun 2016
Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo
Dr Amir Fathi, Massachusetts General Hospital, Boston, USA
Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo ( Dr Amir Fathi, Massachusetts General Hospital, Boston, USA )
11 Jun 2016
Meta-analysis of overall survival in multiple myeloma treated with lenalidomide
Dr Philip McCarthy - Roswell Park Cancer Institute, New York, USA
Meta-analysis of overall survival in multiple myeloma treated with lenalidomide ( Dr Philip McCarthy - Roswell Park Cancer Institute, New York, USA )
11 Jun 2016
Risk adapted therapy for acute myeloid leukaemia
Prof Jorge Sierra - Hospital de Sant Pau, Barcelona, Spain
Risk adapted therapy for acute myeloid leukaemia ( Prof Jorge Sierra - Hospital de Sant Pau, Barcelona, Spain )
11 Jun 2016
Clinical characteristics and prognostic factors of plasmablastic lymphoma patien...
Dr Emmanuelle Tchernonog - CHRU Montpellier, Montpellier, France
Clinical characteristics and prognostic factors of plasmablastic lymphoma patients ( Dr Emmanuelle Tchernonog - CHRU Montpellier, Montpellier, France )
11 Jun 2016
Blinatumomab improves survival of relapsed B-cell leukaemia
Prof Max Topp - University of Würzburg, Würzburg, Germany
Blinatumomab improves survival of relapsed B-cell leukaemia ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
11 Jun 2016
Decoding the risk of thromboembolic events in lymphoma patients
Prof Darko Antic - Clinic For Hematology, Clinical Center Serbia, Belgrade, Serb...
Decoding the risk of thromboembolic events in lymphoma patients ( Prof Darko Antic - Clinic For Hematology, Clinical Center Serbia, Belgrade, Serbia )
11 Jun 2016
SGN-CD33A combined with HMA therapy produces high remission rates among older pa...
Dr Amir Fathi - Massachusetts General Hospital, Boston, USA
SGN-CD33A combined with HMA therapy produces high remission rates among older patients with AML ( Dr Amir Fathi - Massachusetts General Hospital, Boston, USA )
11 Jun 2016
Killer antibodies against AML
Dr Mette Hazenberg - AMC, Amsterdam, The Netherlands
Killer antibodies against AML ( Dr Mette Hazenberg - AMC, Amsterdam, The Netherlands )
11 Jun 2016
Improved survival in adult ALL
Dr Nina Toft - Rigshospitalet, Copenhagen, Denmark
Improved survival in adult ALL ( Dr Nina Toft - Rigshospitalet, Copenhagen, Denmark )
11 Jun 2016
Multiple myeloma highlights from EHA 2016
Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Paul Richardson, Prof Philip ...
Multiple myeloma highlights from EHA 2016 ( Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Paul Richardson, Prof Philip McCarthy )
10 Jun 2016
Activated JAK-STAT signaling co-operates with HOXA9 to drive leukaemia
Dr Charles De Bock - KU Leuven, Leuven, Belgium
Activated JAK-STAT signaling co-operates with HOXA9 to drive leukaemia ( Dr Charles De Bock - KU Leuven, Leuven, Belgium )
10 Jun 2016
SL401 in patients with rare neoplasm
Prof Naveen Pemmaraju - The University of Texas MD Anderson Cancer Center, Houst...
SL401 in patients with rare neoplasm ( Prof Naveen Pemmaraju - The University of Texas MD Anderson Cancer Center, Houston, United States )
10 Jun 2016
RNA regulation of JAK-STAT pathways in CML
Prof Danilo Perrotti - The University of Maryland Baltimore, Baltimore, USA
RNA regulation of JAK-STAT pathways in CML ( Prof Danilo Perrotti - The University of Maryland Baltimore, Baltimore, USA )
10 Jun 2016
Daratumumab shows remarkable benefit in relapsed or refractory MM
Prof Meletios Dimopoulos - University Athens School of Medicine, Athens, Greece
Daratumumab shows remarkable benefit in relapsed or refractory MM ( Prof Meletios Dimopoulos - University Athens School of Medicine, Athens, Greece )
10 Jun 2016
Pre-leukaemic clones that survive chemo linked to higher risk of AML recurrence
Dr Klaus Metzeler - Ludwig-Maximilians-Universität, Munich, Germany
Pre-leukaemic clones that survive chemo linked to higher risk of AML recurrence ( Dr Klaus Metzeler - Ludwig-Maximilians-Universität, Munich, Germany )
10 Jun 2016
Blinatumomab improves survival in ALL patients
Prof Max Topp - University of Würzburg, Würzburg, Germany
Blinatumomab improves survival in ALL patients ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
10 Jun 2016
Stopping tyrosine kinase inhibitors in CML
Dr Johan Richter - Lund University, Sweden
Stopping tyrosine kinase inhibitors in CML ( Dr Johan Richter - Lund University, Sweden )
10 Jun 2016
Evaluation of ibrutinib in treatment of CLL with 17p deletion
Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA
Evaluation of ibrutinib in treatment of CLL with 17p deletion ( Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA )
10 Jun 2016
Nivolumab restores effective anti-tumour response in Hodgkin lymphoma
Dr Anas Younes - Memorial Sloan Kettering Cancer Centre, New York, USA
Nivolumab restores effective anti-tumour response in Hodgkin lymphoma ( Dr Anas Younes - Memorial Sloan Kettering Cancer Centre, New York, USA )
10 Jun 2016
An overview of MCL from EHA 2016
Professor Simon Rule and Professor Steven Le Gouill
An overview of MCL from EHA 2016 ( Professor Simon Rule and Professor Steven Le Gouill )
10 Jun 2016